Skip to content
Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
$164.49M+348%$205.99M+1,229%$111.54M+233%$251.08M+325%-$66.28M-292%
$13.9M-0.3%$13.55M-5.9%$13.51M-4.7%$13.8M-1.3%$13.94M-7.1%
$86.63M-22.4%$70.15M+23.7%$71.63M-21.8%$108.21M+136%$111.68M+25.1%
$326.72M+113%$70.5M+160%$163.56M+273%$325.11M+644%$153.73M+23.8%
$34.68M+143%$21.83M+143%$23.29M+156%$12.14M+190%$14.29M+78.3%
-$363.46M-157%-$25.54M-122%$0+100%$501.11M+1,757%-$141.38M
$36.24M-32.6%$15.71M-64.4%-$448.35M-536%$53.76M-59.1%
$53.61M0.0%$166.01M$376.94M+187%$93.61M-67.3%
$292.04M+109%$48.67M+138%$140.26M+235%$312.97M+692%$139.44M+20.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Alnylam Pharmaceuticals generate?
Alnylam Pharmaceuticals (ALNY) generated $885.9M in operating cash flow over the trailing twelve months.
What is Alnylam Pharmaceuticals's free cash flow?
After $91.9M of capital expenditures, Alnylam Pharmaceuticals's free cash flow was $793.9M over the trailing twelve months, up 1624.2% year over year.
Where does Alnylam Pharmaceuticals's cash flow data come from?
Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.